Cyclooxygenase-2 and inflammation in atherosclerosis

Current Opinion in Pharmacology

Volumn 4, Issue 2, 2004, Pages 116-123

  Linton, MacRae F ^a   Fazio, Sergio ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN E; CELECOXIB; CHOLESTEROL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; HEPARIN; IBUPROFEN; ICOSANOID; INDOMETACIN; INTERLEUKIN 6; LIVER X RECEPTOR; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROSTACYCLIN; ROFECOXIB; SULINDAC; THROMBOXANE A2; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; GENE DELETION; HEART INFARCTION; HEART PROTECTION; HOMEOSTASIS; HUMAN; IMMUNOPATHOGENESIS; LIPID OXIDATION; MACROPHAGE ACTIVATION; MALE; MONOCYTE; MOUSE; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEPTOR DOWN REGULATION; REVIEW; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOSIS; UPREGULATION;

ANIMALS; ARTERIOSCLEROSIS; CYCLOOXYGENASE 2; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; VASCULITIS;

EID: 1842453964     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2003.12.003     Document Type: Review

References (84)

1. Glass C.K. Witztum J.L. Atherosclerosis. the road ahead Cell 104 2001 503-516
2. Smith W.L. Marnett L.J. Prostaglandin endoperoxide synthase: structure and catalysis Biochim Biophys Acta 1083 1991 1-17
3. Dubois R.N. Abramson S.B. Crofford L. Gupta R.A. Simon L.S. Van De Putte L.B. Lipsky P.E. Cyclooxygenase in biology and disease FASEB J 12 1998 1063-1073
4. Raz A. Wyche A. Siegel N. Needleman P. Regulation of fibroblast cyclooxygenase synthesis by interleukin-1 J Biol Chem 263 1988 3022-3028
5. Reed D.W. Bradshaw W.S. Xie W. Simmons D.L. In vivo and in vitro expression of a non-mammalian cyclooxygenase-1 Prostaglandins 52 1996 269-284
6. Wu K.K. Cyclooxygenase-2 induction in congestive heart failure friend or foe? Circulation 98 1998 95-96
7. Chandrasekharan N.V. Dai H. Roos K.L. Evanson N.K. Tomsik J. Elton T.S. Simmons D.L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression Proc Natl Acad Sci U S A 99 2002 13926-13931
8. Vane J.R. Botting R.M. Pharmacodynamic profile of prostacyclin Am J Cardiol 75 1995 3A-10A
9. McAdam B.F. Catella-Lawson F. Mardini I.A. Kapoor S. Lawson J.A. FitzGerald G.A.Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitors of COX-2 Proc Natl Acad Sci U S A 96 1999 272-277
10. Catella-Lawson F. McAdam B. Morrison B.W. Kapoor S. Kujubu D. Antes L. Lasseter K.C. Quan H. Gertz B.J. FitzGerald G.A. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids J Pharmacol Exp Ther 289 1999 735-741
11. Wong E. Huang J. Tagari P. Riendeau D. Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits Atherosclerosis 157 2001 393-402
12. Belton O. Byrne D. Kearney D. Leahy A. Fitzgerald D.J. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis Circulation 102 2000 840-845
13. Cheng Y. Austin S.C. Rocca B. Koller B.H. Coffman T.M. Grosser T. Lawson J.A. FitzGerald G.A. Role of prostacyclin in the cardiovascular response to thromboxane A2 Science 296 2002 539-541
14. Crofford L.J. COX-1 and COX-2 tissue expression: implications and predictions J Rheumatol 24 1997 15-19
15. Appleby S.B. Ristimaki A. Nelson K. Narko K. Hla T. Structure of the human cyclooxygenase-2 gene Biochem J 302 1994 723-737
16. Barbieri S.S. Eligini S. Brambilla M. Tremoli E. Colli S. Reactive oxygen species mediate cyclooxygenase-2 induction during monocyte to macrophage differentiation: critical role of NADPH oxidase Cardiovasc Res 60 2003 187-197
17. Hinson R.M. Williams J.A. Shacter E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2 Proc Natl Acad Sci U S A 93 1996 4885-4890
18. Cao H.J. Wang H.S. Zhang Y. Lin H.Y. Phipps R.P. Smith T.J. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy J Biol Chem 273 1998 29615-29625
19. Callejas N.A. Casado M. Diaz-Guerra M.J. Bosca L. Martin-Sanz P. Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes Hepatology 33 2001 860-867
20. Shankavaram U.T. Lai W.C. Netzel-Arnett S. Mangan P.R. Ardans J.A. Caterina N. Stetler-Stevenson W.G. Birkedal-Hansen H. Wahl L.M. Monocyte membrane type 1-matrix metalloproteinase, Prostaglandin-dependent regulation and role in metalloproteinase-2 activation J Biol Chem 276 2001 19027-19032
21. Wesley II R.B. Meng X. Godin D. Galis Z.S. Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro Arterioscler Thromb Vasc Biol 18 1998 432-440
22. Takayama K. Garcia-Cardena G. Sukhova G.K. Comander J. Gimbrone M.A. Libby Jr. P.Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor J Biol Chem 277 2002 44147-44154
23. Kreuzer J. Denger S. Jahn L. Bader J. Ritter K. von Hodenberg E. Kubler W. LDL stimulates chemotaxis of human monocytes through a cyclooxygenase-dependent pathway Arterioscler Thromb Vasc Biol 16 1996 1481-1487
24. Pomerantz K.B. Nicholson A.C. Hajjar D.P. Signal transduction in atherosclerosis: second messengers and regulation of cellular cholesterol trafficking Adv Exp Med Biol 369 1995 49-64
25. Baker C.S. Hall R.J. Evans T.J. Pomerance A. Maclouf J. Creminon C. Yacoub M.H. Polak J.M. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages Arterioscler Thromb Vasc Biol 19 1999 646-655
26. Yamagata K. Andreasson K.I. Kaufmann W.E. Barnes C.A. Worley P.F. Expression of a mitogen inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids Neuron 11 1993 371-386
27. Langenbach R. Loftin C. Lee C. Tiano H. Cyclooxygenase knockout mice: models for elucidating isoform-specific functions Biochem Pharmacol 58 1999 1237-1246
28. Hansson G.K. Libby P. Schonbeck U. Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis Circ Res 91 2002 281-291
29. Wu Z.L. Liang M.Y. Qiu L.Q. Oxidized low-density lipoprotein decreases the induced nitric oxide synthesis in rat mesangial cells Cell Biochem Funct 16 1998 153-158
30. Eligini S. Colli S. Basso F. Sironi L. Tremoli E. Oxidized low density lipoprotein suppresses expression of inducible cyclooxygenase in human macrophages Arterioscler Thromb Vasc Biol 19 1999 1719-1725
31. Eligini S. Brambilla M. Banfi C. Camera M. Sironi L. Barbieri S.S. Auwerx J. Tremoli E. Colli S. Oxidized phospholipids inhibit cyclooxygenase-2 in human macrophages via nuclear factor-kappaB/IkappaB- and ERK2-dependent mechanisms Cardiovasc Res 55 2002 406-415
32. Banfi C. Colli S. Eligini S. Mussoni L. Tremoli E. Oxidized LDLs influence thrombotic response and cyclooxygenase 2 Prostaglandins Leukot Essent Fatty Acids 67 2002 169-173
33. Dichtl W. Nilsson L. Goncalves I. Ares M.P. Banfi C. Calara F. Hamsten A. Eriksson P. Nilsson J. Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells Circ Res 84 1999 1085-1094
34. Belt A.R. Baldassare J.J. Molnar M. Romero R. Hertelendy F. The nuclear transcription factor NF-kappaB mediates interleukin-1beta-induced expression of cyclooxygenase-2 in human myometrial cells Am J Obstet Gynecol 181 1999 359-366
35. Masferrer J.L. Zweifel B.S. Seibert K. Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice J Clin Invest 86 1990 1375-1379
36. Kanters E. Pasparakis M. Gijbels M.J. Vergouwe M.N. Partouns-Hendriks I. Fijneman R.J. Clausen B.E. Forster I. Kockx M.M. Rajewsky K. et al. Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice J Clin Invest 112 2003 1176-1185
37. Second International Study of Infarct Survival Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988, 2:349-360.
38. Chen Z.M. Sandercock P. Pan H.C. Counsell C. Collins R. Liu L.S. Xie J.X. Warlow C. Peto R. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups Stroke 31 2000 1240-1249
39. Collins R. Baigent C. Sandercock P. Peto R. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists' Collaboration BMJ 309 1994 1215-1217
40. Ridker P.M. Cushman M. Stampfer M.J. Tracy R.T. Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N Engl J Med 336 1997 973-979
41. Bailey J.M. Butler J. Anti-inflammatory drugs in experimental atherosclerosis. I. Relative potencies for inhibiting plaque formation Atherosclerosis 17 1973 515-522
42. Pratico D. Tillmann C. Zhang Z.B. Li H. FitzGerald G.A. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice Proc Natl Acad Sci U S A 98 2001 3358-3363
43. Burleigh M.E. Babaev V.R. Oates J.A. Harris R.C. Gautam S. Riendeau D. Marnett L.J. Morrow J.D. Fazio S. Linton M.F. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice Circulation 105 2002 1816-1823
44. Schonbeck U. Sukhova G.K. Graber P. Coulter S. Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions Am J Pathol 155 1999 1281-1291
45. Mathur S.N. Albright E. Field F.J. Decreased prostaglandin production by cholesterol-rich macrophages J Lipid Res 30 1989 1385-1395
46. Smith L.H. Boutaud O. Breyer M. Morrow J.D. Oates J.A. Vaughan D.E. Cyclooxygenase-2-dependent prostacyclin formation is regulated by low density lipoprotein cholesterol in vitro Arterioscler Thromb Vasc Biol 22 2002 983-988
47. Faour W.H. He Y. He Q.W. de Ladurantaye M. Quintero M. Mancini A. Di Battista J.A. Prostaglandin E2 regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1beta -treated human synovial fibroblasts J Biol Chem 276 2001 31720-31731
48. Hinz B. Brune K. Pahl A. Cyclooxygenase-2 expression in lipopolysaccharide-stimulated human monocytes is modulated by cyclic AMP, prostaglandin E(2), and nonsteroidal anti-inflammatory drugs Biochem Biophys Res Commun 278 2000 790-796
49. Marx N. Sukhova G. Murphy C. Libby P. Plutzky J. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro Am J Pathol 153 1998 17-23
50. Ricote M. Huang J. Fajas L. Li A. Welch J. Najib J. Witztum J.L. Auwerx J. Palinski W. Glass C.K. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein Proc Natl Acad Sci U S A 95 1998 7614-7619
51. Tontonoz P. Nagy L. Alvarez J.G.A. Thomazy V.A. Evans R.M. PPAR-gamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL Cell 93 1998 241-252
52. Inoue H. Tanabe T. Umesono K. Feedback control of cyclooxygenase-2 expression through PPARgamma J Biol Chem 275 2000 28028-28032
53. Lee C.H. Chawla A. Urbiztondo N. Liao D. Boisvert W.A. Evans R.M. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta Science 302 2003 453-457
54. Edwards P.A. Kast H.R. Anisfeld A.M. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis J Lipid Res 43 2002 2-12
55. Joseph S.B. Tontonoz P. LXRs: new therapeutic targets in atherosclerosis? Curr Opin Pharmacol 3 2003 192-197
56. Joseph S.B. McKilligin E. Pei L. Watson M.A. Collins A.R. Laffitte B.A. Chen M. Noh G. Goodman J. Hagger G.N. et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice Proc Natl Acad Sci U S A 99 2002 7604-7609
57. Tangirala R.K. Bischoff E.D. Joseph S.B. Wagner B.L. Walczak R. Laffitte B.A. Daige C.L. Thomas D. Heyman R.A. Mangelsdorf D.J. et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis Proc Natl Acad Sci U S A 99 2002 11896-11901
58. Joseph S.B. Castrillo A. Laffitte B.A. Mangelsdorf D.J. Tontonoz P.Reciprocal regulation of inflammation and lipid metabolism by liver X receptors Nat Med 9 2003 213-219
59. Ross R. Atherosclerosis - an inflammatory disease N Engl J Med 340 1999 115-126
60. Rott D. Zhu J. Burnett M.S. Zhou Y.F. Zalles-Ganley A. Ogunmakinwa J. Epstein S.E. Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice J Am Coll Cardiol 41 2003 1812-1819
61. Olesen M. Kwong E. Meztli A. Kontny F. Seljeflot I. Arnesen H. Lyngdorf L. Falk E. No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice Scand Cardiovasc J 36 2002 362-367
62. Bea F. Blessing E. Bennett B.J. Kuo C.C. Campbell L.A. Kreuzer J. Rosenfeld M.E. Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis Cardiovasc Res 60 2003 198-0204
63. Oshima M. Murai N. Kargman S. Arguello M. Luk P. Kwong E. Taketo M.M. Evans J.F. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor Cancer Res 61 2001 1733-1740
64. Warner T.D. Giuliano F. Vojnovic I. Bukasa A. Mitchell J.A. Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis Proc Natl Acad Sci U S A 96 1999 7563-7568
65. Riendeau D. Charleson S. Cromlish W. Mancini J.A. Wong E. Guay J. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays Can J Physiol Pharmacol 75 1997 1088-1095
66. Chan C.C. Boyce S. Brideau C. Charleson S. Cromlish W. Ethier D. Evans J. Ford-Hutchinson A.W. Forrest M.J. Gauthier J.Y. et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3- phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles J Pharmacol Exp Ther 290 1999 551-560
67. Tangirala R.K. Rubin E.M. Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice J Lipid Res 36 1995 2320-2328
68. Burleigh M.E. Patel M.B. Babaev V.R. Oates J.A. Morrow J.D. Fazio S. Linton M.F. Inhibition of cyclooxygenase-2 decreases atherosclerotic lesion formation in apoe deficient mice Circulation 102 2000 42
69. Krul E.S. Napawan N. Butteiger D.T. Hayes K. Krause L. Freidrich G.E. Broschat K.O. Keller B.T. Atherosclerosis is reduced in cholesterol-fed ApoE(-/-) mice administered an ASBT inhibitor or a selective COX-2 inhibitor Arterioscler Thromb Vasc Biol 22 2002 P409
70. Babaev V.R. Patel M.B. Semenkovich C.F. Fazio S. Linton M.F. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice J Biol Chem 275 2000 26293-26299
71. Lehmann J.M. Lenhard J.M. Oliver B.B. Ringold G.M. Kliewer S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs J Biol Chem 272 1997 3406-3410
72. Linton M.F. Atkinson J.B. Fazio S. Prevention of atherosclerosis in apoE deficient mice by bone marrow transplantation Science 267 1995 1034-1037
73. Linton M.F. Fazio S. Macrophages, lipoprotein metabolism, and atherosclerosis: insights from murine bone marrow transplantation studies Curr Opin Lipidol 10 1999 97-105
74. Bombardier C. Laine L. Reicin A. Shapiro D. Burgos-Vargas R. Davis B. Day R. Ferraz M.B. Hawkey C.J. Hochberg M.C. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N Engl J Med 343 2000 1520-1528
75. Dalen J.E. Selective COX-2 inhibitors, NSAIDs, aspirin, and myocardial infarction Arch Intern Med 162 2002 1091-1092
76. Konstam M.A. Weir M.R. Reicin A. Shapiro D. Sperling R.S. Barr E. Gertz B.J. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib Circulation 104 2001 2280-2288
77. Reicin A.S. Shapiro D. Sperling R.S. Barr E. Yu Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone) Am J Cardiol 89 2002 204-209
78. Ray W.A. Stein C.M. Daugherty J.R. Hall K. Arbogast P.G. Griffin M.R. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease Lancet 360 2002 1071-1073
79. Silverstein F.E. Faich G. Goldstein J.L. Simon L.S. Pincus T. Whelton A. Makuch R. Eisen G. Agrawal N.M. Stenson W.F. et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study JAMA 284 2000 1247-1255
80. White W.B. Faich G. Borer J.S. Makuch R.W. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib Am J Cardiol 92 2003 411-418
81. Chenevard R. Hurlimann D. Bechir M. Enseleit F. Spieker L. Hermann M. Riesen W. Gay S. Gay R.E. Neidhart M. et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease Circulation 107 2003 405-409
82. Altman R. Luciardi H.L. Muntaner J. Del Rio F. Berman S.G. Lopez R. Gonzalez C. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study Circulation 106 2002 191-195
83. Mukherjee D. Nissen S.E. Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors JAMA 286 2001 954-959
84. FitzGerald G.A.Patrono C.The Coxibs, selective inhibitors of cyclooxygenase-2 N Engl J Med 345 2001 433-442